MX2009004071A - Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. - Google Patents
Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos.Info
- Publication number
- MX2009004071A MX2009004071A MX2009004071A MX2009004071A MX2009004071A MX 2009004071 A MX2009004071 A MX 2009004071A MX 2009004071 A MX2009004071 A MX 2009004071A MX 2009004071 A MX2009004071 A MX 2009004071A MX 2009004071 A MX2009004071 A MX 2009004071A
- Authority
- MX
- Mexico
- Prior art keywords
- histamine
- sulfonyl
- treatment
- disorders
- modulators
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 3
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract 2
- 235000010290 biphenyl Nutrition 0.000 title 1
- 239000004305 biphenyl Substances 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 206010041349 Somnolence Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000001573 Cataplexy Diseases 0.000 abstract 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010062519 Poor quality sleep Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000032140 Sleepiness Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 206010020765 hypersomnia Diseases 0.000 abstract 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85261006P | 2006-10-17 | 2006-10-17 | |
| US93435807P | 2007-06-11 | 2007-06-11 | |
| PCT/US2007/022086 WO2008048609A1 (en) | 2006-10-17 | 2007-10-16 | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004071A true MX2009004071A (es) | 2009-04-28 |
Family
ID=39149258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004071A MX2009004071A (es) | 2006-10-17 | 2007-10-16 | Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100240653A1 (enExample) |
| EP (1) | EP2074086B1 (enExample) |
| JP (1) | JP2010506918A (enExample) |
| KR (1) | KR20090069333A (enExample) |
| AR (1) | AR063226A1 (enExample) |
| AT (1) | ATE512948T1 (enExample) |
| AU (1) | AU2007313180A1 (enExample) |
| CA (1) | CA2665204A1 (enExample) |
| CL (1) | CL2007002977A1 (enExample) |
| EA (1) | EA200970386A1 (enExample) |
| IL (1) | IL197892A0 (enExample) |
| MX (1) | MX2009004071A (enExample) |
| PA (1) | PA8750901A1 (enExample) |
| PE (1) | PE20081462A1 (enExample) |
| TW (1) | TW200823204A (enExample) |
| WO (1) | WO2008048609A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754238B2 (en) | 2003-07-22 | 2014-06-17 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| CN101801924A (zh) * | 2007-06-08 | 2010-08-11 | 艾尼纳制药公司 | (r)-1-{2-[4’-(3-甲氧基-丙烷-1-磺酰基)-联苯-4-基]-乙基}-2-甲基-吡咯烷的结晶形式及与其相关的组合物和方法 |
| JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体 |
| US20110021538A1 (en) * | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| CN102066319A (zh) * | 2008-04-16 | 2011-05-18 | 艾尼纳制药公司 | 用于合成(r)-1-{2-[4’-(3-甲氧基丙-1-磺酰基)-联苯-4-基]-乙基}-2-甲基-吡咯烷的方法 |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| HRP20180589T1 (hr) * | 2008-10-28 | 2018-05-18 | Arena Pharmaceuticals, Inc. | Pripravci modulatora serotoninskog receptora 5-ht2a koji su korisni za liječenje s njim povezanih poremećaja |
| GB201005511D0 (en) | 2010-03-31 | 2010-05-19 | Takeda Pharmaceutical | Compounds and their use |
| FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| ES2886914T3 (es) * | 2013-01-09 | 2021-12-21 | Arena Pharm Inc | Acido (R)-3-(4'-(2-(2-metilpirrolidin-1-il)etil)-bifenil-4-il)propanoico como moduladores del receptor de histamina H3 para el tratamiento de trastornos cognitivos |
| RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
| TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物 |
| WO2020092604A1 (en) * | 2018-10-30 | 2020-05-07 | Concert Pharmaceuticals, Inc. | Deuterated pitolisant |
| WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
| CN115160584B (zh) * | 2022-07-06 | 2024-03-22 | 西北工业大学 | 一种基于阳离子-π与静电作用协同构筑异质孔超分子有机框架及制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352707A (en) * | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
| US5217986A (en) * | 1992-03-26 | 1993-06-08 | Harbor Branch Oceanographic Institution, Inc. | Anti-allergy agent |
| DE69333489T2 (de) * | 1992-09-14 | 2005-04-14 | Takeda Chemical Industries, Ltd. | Heterocyclische Verbindungen und ihre Verwendung als Angiotensin II Antagonisten |
| US5541217A (en) * | 1995-05-17 | 1996-07-30 | Ortho Pharmaceutical Corporation | 4-arylcyclopenta[c]pyrrole analgesics |
| US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| DE19937537A1 (de) * | 1999-08-09 | 2001-03-08 | Gruenenthal Gmbh | Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate |
| US20040044029A1 (en) * | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| US7244852B2 (en) * | 2003-02-27 | 2007-07-17 | Abbott Laboratories | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
| GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| JP4777974B2 (ja) * | 2004-04-01 | 2011-09-21 | イーライ リリー アンド カンパニー | ヒスタミンｈ３受容体作用物質、製剤および治療的使用 |
| US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
| US7145005B2 (en) * | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
| ATE429426T1 (de) * | 2004-09-07 | 2009-05-15 | Banyu Pharma Co Ltd | Carbamoylsubstituiertes spiro-derivat |
| JP2008521847A (ja) * | 2004-12-03 | 2008-06-26 | エフ．ホフマン−ラ ロシュ アーゲー | Ｈ３拮抗剤としての３−置換ピリジン誘導体 |
| AU2006207712A1 (en) * | 2005-01-19 | 2006-07-27 | F. Hoffmann-La Roche Ag | 5-aminoindole derivatives |
| US20060188960A1 (en) * | 2005-02-18 | 2006-08-24 | Waters Stephen M | Chimeric histamine H3 receptor |
| WO2006138714A2 (en) * | 2005-06-17 | 2006-12-28 | Janssen Pharmaceutica N.V. | Naphthyridine compounds |
| UA96424C2 (ru) * | 2005-09-16 | 2011-11-10 | Янссен Фармацевтика Н.В. | Циклопропил амины как модуляторы н3 рецепторов гистамина |
| BRPI0619268A2 (pt) * | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
| EP1966143A2 (en) * | 2005-12-21 | 2008-09-10 | Schering Corporation | Substituted aniline derivatives useful as histamine h3 antagonists |
| EP1994022A2 (en) * | 2006-03-15 | 2008-11-26 | Wyeth a Corporation of the State of Delaware | N-substituted-azacyclylamines as histamine-3 antagonists |
| EP2027086B1 (en) * | 2006-05-19 | 2011-11-16 | Wyeth LLC | N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists |
| CA2653940C (en) * | 2006-05-30 | 2015-07-14 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| WO2008005338A1 (en) * | 2006-06-29 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| US7507736B2 (en) * | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
| US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
| US7557108B2 (en) * | 2007-02-07 | 2009-07-07 | Hoffmann-La Roche Inc. | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones |
| WO2008144305A1 (en) * | 2007-05-18 | 2008-11-27 | Janssen Pharmaceutica N.V. | Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators |
| KR20100020487A (ko) * | 2007-05-24 | 2010-02-22 | 와이어쓰 엘엘씨 | 히스타민-3 길항제로서 아자시클릴벤즈아미드 유도체 |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| WO2009036144A1 (en) * | 2007-09-12 | 2009-03-19 | Wyeth | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| WO2009067406A1 (en) * | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| US8236792B2 (en) * | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
-
2007
- 2007-09-28 TW TW096136478A patent/TW200823204A/zh unknown
- 2007-10-10 AR ARP070104474A patent/AR063226A1/es not_active Application Discontinuation
- 2007-10-16 EP EP07852791A patent/EP2074086B1/en active Active
- 2007-10-16 JP JP2009533349A patent/JP2010506918A/ja not_active Withdrawn
- 2007-10-16 EA EA200970386A patent/EA200970386A1/ru unknown
- 2007-10-16 MX MX2009004071A patent/MX2009004071A/es active IP Right Grant
- 2007-10-16 KR KR1020097009992A patent/KR20090069333A/ko not_active Withdrawn
- 2007-10-16 WO PCT/US2007/022086 patent/WO2008048609A1/en not_active Ceased
- 2007-10-16 AU AU2007313180A patent/AU2007313180A1/en not_active Abandoned
- 2007-10-16 CA CA002665204A patent/CA2665204A1/en not_active Abandoned
- 2007-10-16 AT AT07852791T patent/ATE512948T1/de not_active IP Right Cessation
- 2007-10-16 PE PE2007001398A patent/PE20081462A1/es not_active Application Discontinuation
- 2007-10-16 US US12/445,795 patent/US20100240653A1/en not_active Abandoned
- 2007-10-17 PA PA20078750901A patent/PA8750901A1/es unknown
- 2007-10-17 CL CL200702977A patent/CL2007002977A1/es unknown
-
2009
- 2009-04-05 IL IL197892A patent/IL197892A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8750901A1 (es) | 2009-03-31 |
| AU2007313180A1 (en) | 2008-04-24 |
| CA2665204A1 (en) | 2008-04-24 |
| JP2010506918A (ja) | 2010-03-04 |
| US20100240653A1 (en) | 2010-09-23 |
| PE20081462A1 (es) | 2008-10-18 |
| WO2008048609A1 (en) | 2008-04-24 |
| CL2007002977A1 (es) | 2008-06-06 |
| EP2074086A1 (en) | 2009-07-01 |
| EA200970386A1 (ru) | 2009-10-30 |
| KR20090069333A (ko) | 2009-06-30 |
| EP2074086B1 (en) | 2011-06-15 |
| ATE512948T1 (de) | 2011-07-15 |
| TW200823204A (en) | 2008-06-01 |
| AR063226A1 (es) | 2009-01-14 |
| IL197892A0 (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009004071A (es) | Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. | |
| WO2008153958A3 (en) | Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto | |
| MX2009012430A (es) | Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas. | |
| NZ595625A (en) | Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators | |
| SG163526A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| MX2010002890A (es) | 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. | |
| NZ573565A (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| NO20082264L (no) | Histamin-3 reseptorantagonister | |
| NZ617334A (en) | Cyclopropyl amine derivatives | |
| EP2063778A4 (en) | METHOD AND SYSTEM FOR MONITORING RESPIRATORY ACTIVITY AND TREATMENT OF ATOMS SUCH AS FOR EXAMPLE SLEEP APNEA | |
| NO20083710L (no) | Dihydrotienopyrimidin for behandling av betennelsesforstyrrelser | |
| RU2016105971A (ru) | Применение флекаинида в качестве антиконнексинового средства и способ потенцирования эффектов психотропных лекарственных средств | |
| NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| MX2011007774A (es) | Derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
| MX2009007782A (es) | Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma. | |
| NO20083197L (no) | Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese | |
| BRPI0721088B8 (pt) | processo para a preparação de derivados de piperazinil e diazepanil benzamida | |
| NI200700084A (es) | Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada | |
| MX2011011273A (es) | Derivados de isoxazol-pirazol. | |
| MX2011008336A (es) | Derivados de dihidroquinolinona. | |
| CO6331428A2 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| PT2221298E (pt) | Derivados de fenilpirazole | |
| NZ595627A (en) | Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators | |
| WO2007061741A3 (en) | Modulators of the h3 receptor useful for the treatment of disorders related thereto | |
| JP2010529130A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |